EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- ACCOLATE
- Benlysta 120 mg
- Protopic 0.1% ointment
- Aminophylline injection BP 500 mg/2 ml
- Gastrocote Liquid
- Equasym XL 10 mg, 20 mg or 30 mg Capsules
- Tazocin 2g/0.25g and 4g/0.5g Powder for Solution for Injection or Infusion
- Imodium Plus Caplets GSL
- Ilaris 150mg powder for solution for injection
- Voltarol 25mg, 50mg Rapid Tablets
- E45 Itch Relief Cream
- Lescol XL 80 mg Prolonged Release Tablets
- Onbrez Breezhaler 300 microgram inhalation powder, hard capsules
- Heparin calcium 25,000 I.U./ml Solution for injection or concentrate for solution for infusion
- Kamillosan Ointment
- Hyoscine Hydrobromide 400 micrograms/ml Solution for Injection
- Abilify Tablets, Orodispersible Tablets, Oral Solution (Otsuka & Bristol-Myers Squibb)
- Anugesic HC Cream
- Arimidex 1mg Film-Coated Tablet
- Avodart 0.5mg soft capsules
- Gabapentin 100 mg Capsules
- Dovonex Ointment
- Premique Low Dose 0.3mg/1.5mg Modified Release Tablets
- Premique 0.625mg/5mg Coated Tablets
- Innohep 20,000 IU/ml and Innohep syringe 20,000 IU/ml
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Accupro Tablets 5mg, 10mg, 20mg & 40mg
- Acular
- Betaferon
- Cimzia 200 mg solution for injection
- Olanzapine 2.5mg Film-coated Tablets
- Pentasa Slow Release Tablets 1g
- COZAAR 2.5 mg/ml powder and solvent for oral suspension
- Daktarin Gold 2% Cream
- Edronax 4mg Tablets
- COZAAR 12.5 mg, 25 mg, 50 mg and 100 mg Film-Coated Tablets
- Tobi 300 mg/5 ml Nebuliser Solution
- Elocon Cream
- Famciclovir 125 mg Tablets
- Famciclovir 250mg Tablets
Atopic Dermatitis
Please note- The EPG Atopic Dermatitis Knowledge Centre is for Doctors and other Healthcare Professionals. Enter the Atopic Dermatitis Knowledge Centre.
Atopic dermatitis, a chronic inflammatory skin disorder, affects 10–30% of children and 1–3% of adults1,2 in developed countries.
Atopic dermatitis has traditionally been characterised by periods of exacerbations, known as flares, interspersed with periods of apparent remission. It affects patients to varying degrees and is categorised as mild, moderate or severe. The progression of atopic dermatitis also differs considerably from person to person.
The precise cause of the disease is poorly understood but the most common form, extrinsic atopic dermatitis, is strongly associated with a hypersensitivity reaction to environmental allergens.
The specific combination of signs and symptoms associated with atopic dermatitis varies from person to person. However, patients will usually suffer from dry, erythematous skin, with pruritus being a core symptom of the condition.
Following a diagnosis of atopic dermatitis, the choice of management strategy depends on the severity of the condition, and should take into account the patient’s and their family’s needs and concerns.
There are a number of different treatment options currently available for atopic dermatitis including non-pharmacological options like emollient creams to improve symptoms, and pharmacological options, such as topical corticosteroids or topical calcineurin inhibitors.
Enter the Atopic Dermatitis Knowledge Centre
What’s in the Atopic Dermatitis Knowledge Centre?
- Home
- Feedback
- Areas of the body commonly affected by atopic dermatitis
- Assessment
- Diagnosis
- Education
- Non-pharmacological therapy
- Pharmacological therapy
- General Management
- Overview
- Signs and symptoms of atopic dermatitis
- Glossary
- References
- Resources - Websites and Materials
- Non-pharmacological treatments
- Treatment Overview
- Focus on LOCOID
- Focus on PROTOPIC
- Topical calcineurin inhibitors
- Pharmacological treatment - Topical corticosteroids
- Phototherapy
- PROTOPIC - Efficacy and Safety
- PROTOPIC - Frequently asked questions, Topical calcineurin inhibitors
- PROTOPIC - Mode of Action
- Treatment Summary
- Treatment Adjuncts
- Burden
- Causes
- Definition
- Environmental factors
- Genetic factors
- Immune system dysfunction
- Skin barrier function
- Pathophysiology
- Prevalence
References
1. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-7.
2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351: 1225-32.
